First-in-Human Study of CH5132799, an Oral Class I PI3K...

Clinical Cancer Research 2014 / 12 Vol. 20; Iss. 23

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

Blagden, S., Olmin, A., Josephs, D., Stavraka, C., Zivi, A., Pinato, D. J., Anthoney, A., Decordova, S., Swales, K., Riisnaes, R., Pope, L., Noguchi, K., Shiokawa, R., Inatani, M., Prince, J., Jones,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
20
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-14-1315
Date:
December, 2014
File:
PDF, 656 KB
english, 2014
Conversion to is in progress
Conversion to is failed